Dublin biopharma developing GH001, a treatment for depression and other psychiatric conditions.
Founders
Theis Terwey(Germany · ♂)— He co-founded GH Research in 2018 to develop a proprietary inhalable 5-MeO-DMT formulation (GH001) for treatment-resistant depression, serving as founding CEO until 2024.
Magnus C. Halle(♂)— Co-founded GH Research to advance rapid-acting psychedelic therapeutics for mental-health disorders.
Team & hubs
Members see the full profile
Create a free EquityFlow account to see GH Research's 1 funding round, 3 investors, 12 similar companies.